Farr Miller & Washington LLC DC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 16.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 376,120 shares of the company’s stock after selling 72,856 shares during the quarter. Johnson & Johnson makes up about 4.9% of Farr Miller & Washington LLC DC’s investment portfolio, making the stock its 2nd largest position. Farr Miller & Washington LLC DC’s holdings in Johnson & Johnson were worth $55,997,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the third quarter valued at about $1,519,000. Haverford Financial Services Inc. increased its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Haverford Financial Services Inc. now owns 54,808 shares of the company’s stock valued at $8,160,000 after acquiring an additional 704 shares in the last quarter. Heritage Wealth Advisors increased its holdings in shares of Johnson & Johnson by 2.6% during the third quarter. Heritage Wealth Advisors now owns 75,723 shares of the company’s stock valued at $11,274,000 after acquiring an additional 1,908 shares in the last quarter. Illinois Municipal Retirement Fund increased its holdings in shares of Johnson & Johnson by 379.7% during the third quarter. Illinois Municipal Retirement Fund now owns 46,929 shares of the company’s stock valued at $6,987,000 after acquiring an additional 37,146 shares in the last quarter. Finally, CWH Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 2.5% during the third quarter. CWH Capital Management Inc. now owns 18,694 shares of the company’s stock valued at $2,783,000 after acquiring an additional 459 shares in the last quarter. 67.44% of the stock is owned by institutional investors and hedge funds.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is owned by company insiders.
Several research firms have recently issued reports on JNJ. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a report on Friday, November 20th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Cantor Fitzgerald increased their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $164.93.
Shares of NYSE JNJ opened at $144.68 on Tuesday. The stock has a market capitalization of $380.88 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The firm’s 50 day simple moving average is $144.85 and its 200-day simple moving average is $146.39. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. The business had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the company earned $2.12 EPS. Analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.79%. Johnson & Johnson’s payout ratio is 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Forex
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.